vTv Therapeutics (VTVT)
NASDAQ:VTVT
Want to see VTVT full AI Analyst Report?
VTVT Stock Chart & Stats
$38.12
$0.06(0.41%)
At close: 4:00 PM EST
$38.12
$0.06(0.41%)
Day’s Range― - ―
52-Week Range$14.00 - $44.00
Previous CloseN/A
Volume611.00
Average Volume (3M)5.07K
Market Cap
$124.43M
Enterprise Value-$10.80M
Total Cash (Recent Filing)$98.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)118.2
Beta0.68
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding3,938,654
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda15.11
Forecast
1Y Price Target
$54.80Price Target Upside43.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$13.33M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and materially improved equity reduce solvency risk and give management flexibility to fund clinical programs or absorb delays. This stronger capital structure is a durable buffer that supports multi-month execution toward Phase 3 readouts and strategic options without immediate creditor pressure.
Late-stage, Differentiated Pipeline AssetCadisegliatin’s Breakthrough designation and Phase 3 status create a durable strategic asset: a potential first oral adjunct for type 1 diabetes addressing a large unmet market. A successful readout increases odds of commercial partnerships, licensing or non-dilutive funding, altering the company’s long-term funding and growth prospects.
Near-term Funding FlexibilityAn expanded at-the-market program, combined with an $88.9M year-end cash balance and a $20M receipt in Feb 2026, provides durable financing optionality. This reduces immediate liquidity constraints, allowing management to fund the Phase 3 program and seek partnerships without forced, urgent capital raises.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow shows the business remains cash consuming and not self-funding. Over the next several months this creates structural dependence on external financing or partnerships to sustain trial activity and increases dilution risk if milestones or financing windows slip.
Ongoing Operating LossesPersistent negative operating results indicate the core business has not reached sustainable profitability; recent positive net income appears driven by non‑operating items. This limits internal capital generation and leaves execution reliant on external funding or successful commercialization of trial assets.
Revenue Inconsistency / Lack Of Commercial SalesAn inconsistent, largely non‑recurring revenue profile reflects a pipeline-driven model without commercial product cashflows. This structural lack of recurring sales heightens dependence on milestone payments and financings, increasing vulnerability to trial delays or negative outcomes over a multi-month horizon.
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $14.00 and its highest was $44.00 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is $124.43M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 146 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on May 13, 2026. The company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 3,938,654 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of $1.65 in its last earnings report, beating expectations of $0.21. Following the earnings report the stock price went up 21.364%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in VTVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
vTv Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.80 (43.76% Upside)
$54.80 (43.76% Upside)
Blogger Sentiment
Bullish
VTVT Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.40%
12-Months-Change
Fundamentals
Return on Equity
3.96%
Trailing 12-Months
Asset Growth
208.53%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Stock 12 Month Forecast
Average Price Target
$54.80
▲(43.76% Upside)
Technical Analysis
Ownership Overview
11.52% Insiders
10.03% Mutual Funds
19.44% Other Institutional Investors
56.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---